A Study of Expression of Epidermal Growth Factor Receptor(EGFR) and Vascular endothelial growth factor (VEGF) in Epithelial Ovarian Neoplasms

Ovarian carcinoma is the 6th most common carcinoma among women in the world and forms 1.7 to 8.7% of female cancers in India. It is the most common cause of gynecological cancer death in women. Surface epithelial ovarian carcinoma accounts for 90 to 95% of ovarian malignancies. EGFR and VEGF both have diagnostic and therapeutic implications. Both markers were found to be independent prognostic factors in ovarian neoplasms. This is just a hospital based study that may not reflect the exact occurrence in the community as a whole. There is a wide arena of community based studies and research activities being carried out with these two markers - opening up newer dimensions and horizons in the ‘early diagnosis’ and 79 ‘chemotherapeutic approaches’ with anti EGFR and VEGF antibodies in the battle against this ‘silent killer’ called ‘Cancer Ovary’